Introduction
Tamoxifen, a selective estrogen receptor modulator, is widely used drug for the treatment of estrogen-receptor positive breast cancer (Furr and Jordan, 1984) . CYP3A4 is the major enzyme responsible for the N-demethylation of tamoxifen and 4-hydroxylation is primarily mediated by CYP2D6 (Figure 1) , although a number of human P450s can metabolize tamoxifen (Mani et al., 1993; Crewe et al., 2002) . Tamoxifen is a prodrug since metabolic activation is required for maximal biological activity (Mani et al., 1993; Crewe et al., 2002) and two of its metabolites, 4OHtam and 4OHNDtam, have markedly higher affinity for estrogen receptor than tamoxifen itself (Jordan, 1982; Johnson et al., 2004) . Tamoxifen undergoes extensive metabolism to a variety of primary and secondary metabolites by various cytochrome P450 enzymes (Furr and Jordan, 1984) . Bioactivation of tamoxifen has been found to result in the formation of covalent adducts of its metabolites with rat and human microsomal proteins. At least three different reactive intermediates are known to be formed including a carbocation, an O-quinone and a quinone methide (Phillips et al., 1994a; Phillips et al., 1994b; Dehal and Kupfer, 1996; Moorthy et al., 1996) and studies have indicated it is the covalent binding of the metabolites to DNA or protein that is responsible for toxicity (Dehal and Kupfer, 1996) . Treatment with tamoxifen has also been associated with a relatively high incidence of endometrial cancer in women (Andersson et al., 1991; Fisher et al., 1994) and tamoxifen has been shown to be a hepatocarcinogen in rats (Divi et al., 1999) .
Since tamoxifen's approval by FDA as a chemopreventive agent, studies have been done on the formation and identification of its reactive metabolites (Fisher et al., 1998) . Research has identified a variety of functional groups that can be bioactivted to give reactive intermediates leading to toxicity. Formation of a quinone methide is known to be one of the major routes of (Dehal and Kupfer, 1996) . The quinone methide can also be formed by the initial hydroxylation of tamoxifen to give 4OHtam which can then undergo two electron oxidation to form the quinone methide (Thompson et al., 1995) .
Cytochrome P4502B6 is involved in the metabolic activation and inactivation of a variety of endogenous substrates as well as a large number of clinically important drugs that include bupropion, efavirenz, cyclophosphamide, and tamoxifen (Ekins and Wrighton, 1999; Hesse et al., 2000) . Two studies have reported higher levels of expression of CYP2B6 in estrogen receptor positive breast tumors (Hellmold et al., 1998; Lo et al., 2010) and that could lead to vulnerability to damage through bioactivation of compounds metabolized by this enzyme.
Tamoxifen has also been shown to act as a phenobarbital-like inducer in rats causing up regulation of the CYP2B and 3A enzymes at doses comparable to doses normally administered in humans (White et al., 1993; Nuwaysir et al., 1995; Ekins and Wrighton, 1999) . It has been suggested that treatment with tamoxifen over time might change the rates and relative proportions of tamoxifen metabolites formed as a result of induction of CYP2B6 (Crewe et al., 2002) . Relatively little is known about the contribution of CYP2B6 to the overall metabolism of tamoxifen. However, it has been shown that 4OHtam formation is inhibited 13% by a monoclonal antibody against CYP2B6 suggesting a minor role of CYP2B6 in 4OHtam formation (Coller et al., 2002) . CYP2B6 has been shown to have significant catalytic activity for the metabolism of tamoxifen at high substrate concentrations. Metabolism of 250 µM tamoxifen by CYP2B6 in a reconstituted system exhibited a rate of formation of 4OHtam of 2.6 pmol/mg of D M D # 4 7 2 6 6 6 protein/min (Crewe et al., 2002) . We have previously shown that purified CYP2B6 can metabolize tamoxifen to N-desmethyl tam, 4OHtam, and 4'OHtam and that tamoxifen is a mechanism-based inactivator of CYP2B6 and the kinetic parameters for 2B6 inactivation were determined (Sridar et al., 2002) . However, the mechanism of inactivation was not investigated.
This has prompted us to conduct further studies on the bioactivation of tamoxifen catalyzed by CYP2B6. In the presence of glutathione ethyl ester, 4OHtam quinone methide conjugate was detected when CYP2B6 was incubated with tamoxifen. In addition, the site of covalent (Hanna et al., 2000) . P450 reductase and cytochrome b 5 were purified as described previously (Hanna et al., 1998; Lin et al., 2005) .
In vitro trapping of reactive metabolites of tamoxifen with GSHEE. The reaction mixture for the trapping and identification of the glutathione ethyl ester adducts contained 0.25 nmol of recombinant purified 2B6, 0.5 nmol of reductase, 0.25 nmol of b 5 , 100 units of catalase, and 10 mM GSHEE in 50 mM potassium phosphate buffer, pH 7.4, in a final volume of 500 µl. The final concentration of tamoxifen was 60 µM. The reaction was initiated by the addition of 1.2 mM NADPH with control samples receiving the same volume of water. The reaction samples were incubated at 37°C for 45 min and the reactions were terminated by the addition of 5 volumes of acetonitrile. The reaction mixtures were centrifuged at 13,200g at room temperature for 10 min. The supernatants were transferred to new tubes and dried under a stream of nitrogen gas. The residue was suspended in 50 % acetonitrile in water (75 µl) and 50 µL aliquots were injected onto the LC/MS for further analysis. HPLC separation of the tamoxifen glutathione ethyl ester adducts was carried out using a Phenomenox Luna C18 reverse phase column (4.6×100 mm; Phenomenox, Torrance, CA Packard 1100 series HPLC system (Agilent, Palo Alto, CA). The sheath gas was set at 80 arbitrary units and the auxiliary gas was set at 15 arbitrary units. The spray voltage was 5kV and the capillary temperature was 180°C. Data were acquired in the positive ion mode using the Xcalibur software with two data dependent scans for the two most intense ions.
Trapping of 4OHtamoxifen metabolites by GSHEE. The reconstitution and incubation
conditions for the metabolism of 4OHtam by CYP2B6 were carried out in the presence of GSHEE exactly as described above. The final concentration of 4OHtam used in the incubation reaction was 90 µM. Reactions and analyses of the products were carried out as above.
Quinone methide trapping using human liver microsomes. The in vitro formation of hydroxytamoxifen quinone methides and trapping with GSHEE was investigated in human liver microsomes by incubating tamoxifen with human liver microsomal protein obtained from BD Biosciences. Microsomes (5 µg) were diluted to a volume of 500 µl with 0.5 M potassium phosphate buffer (pH 7.4), catalase (100 units) and 90 µM of tamoxifen. The incubation and inactivation of the samples were carried out as described above. Extraction and analysis conditions were carried out as described for reactive metabolite trapping. µM. Incubations were carried out at 37° for 10 min in the absence of NADPH as a negative control or in the presence of NADPH. The samples were then resolved on an Agilent Zorbax C3 column (3.0 ×150 mm, 3.5 µm) eluted with 40% acetonitrile, 0.1 % TFA at a flow rate of 300 µl/min. The proteins were eluted using a linear gradient to 90% B over 40 min before returning the column to equilibration conditions. The samples were analyzed using a ThermoQuest LCQ ion trap mass spectrometer (Thermo Fisher Scientific, Waltham, MA) interfaced with a Hewlett
ESI-LC-MS
Packard 1100 series high-performance liquid chromatography system (Hewlett Packard, Palo
Alto, CA) and the spectra obtained for the control and the inactivated samples were then deconvoluted using Thermoquest Bioworks to determine the masses of the proteins. The ESI conditions were as follows: the auxiliary gas was set at 90 (arbitrary units), sheath gas 30 (arbitrary units), the spray voltage was 4.2kV and the capillary temperature was 230 °C. The peptides were identified automatically using the SEQUEST BioWorks computer program, which correlated the experimental tandem mass spectra against the theoretical tandem mass spectra from amino acid sequences obtained from the National Center for Biotechnology A GSHEE adduct exhibiting a molecular ion at m/z 719 and eluting at 16.6 min was observed similar to that seen when tamoxifen was incubated with CYP2B6 in a reconstituted system. The peak eluting at 16.6 min with m/z 719 was not seen in control samples. Figure 4A shows the extracted ion chromatogram of the GSHEE adduct with m/z 719 and Figure 4B shows the MS/MS spectrum of the GSHEE adduct. The MS/MS fragmentation of the peak with m/z 719 was similar to that seen with the adduct identified when CYP2B6 was incubated with tamoxifen ( Figure 4C ). 388 Da between that expected for b 6 and the observed b 6 ion indicated that the modified residue is that glutamine at position 193. Many of the singly charged fragment ions of both the y and b ions were observed with good intensity in the MS/MS analysis. In the Sequest search, the peptide was identified with a probability score of 2.8 ×10 -8 , a Sp value of 643, and XCorr of 3.9 which exceeded the criteria specified in the Methods section. Manual interpretation of the MS/MS spectra was done using X-calibur to verify the peptide identification. These data also support the conclusion that modification of the peptide occurred at Gln193. The mass of the corresponding unmodified parent peptide was seen at MH + 967 in the control sample (data not shown).
This article has not been copyedited and formatted. The final version may differ from this version. formation through 4OHtam and not catechol formation while P450s 2D6 and 3A5 generated catechol metabolite formation and not drug-protein adduct formation. We were able to successfully identify and characterize a P450 adduct using recombinant purified CYP2B6.
CYP2B6 apoprotein in control samples eluted at 24 min and scanning across this peak yielded a protein envelope that was deconvoluted to give a mass of 54373Da (inset in Figure 5 ).
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